Novartis already owned 44 percent of Chiron’s shares and acquired the remaining 56 percent on April 19 in a deal estimated at $5.4 billion (€4.3 billion). The company said it paid $48 (€33) a share.
Novartis President and CEO Daniel Vasella said the deal allows the company to extend its license and access new strategic platforms in the vaccine and diagnostics fields.
“With our sound base of innovative vaccines, complemented by generic drugs, over-the-counter treatment and now preventive medicines in the form of vaccines, Novartis offers a complete range of treatments for patients and doctors around the world,” Vasella said.
New
